ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 79 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $764,295 | -44.6% | 143,935 | -0.6% | 0.00% | 0.0% |
| Q2 2023 | $1,380,087 | +3.2% | 144,815 | +19.2% | 0.00% | -50.0% |
| Q1 2023 | $1,336,885 | -28.1% | 121,535 | -3.4% | 0.00% | 0.0% |
| Q4 2022 | $1,860,648 | -25.6% | 125,821 | -3.8% | 0.00% | -50.0% |
| Q3 2022 | $2,501,000 | +5.0% | 130,724 | +17.0% | 0.00% | +33.3% |
| Q2 2022 | $2,383,000 | +34.4% | 111,757 | +21.5% | 0.00% | +50.0% |
| Q1 2022 | $1,773,000 | +118.9% | 91,988 | +166.5% | 0.00% | +100.0% |
| Q4 2021 | $810,000 | +217.6% | 34,523 | +283.2% | 0.00% | – |
| Q4 2020 | $255,000 | – | 9,010 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8,684,232 | $165,956,000 | 12.78% |
| Bain Capital Life Sciences Investors, LLC | 3,000,000 | $57,330,000 | 6.84% |
| Pivotal bioVenture Partners Investment Advisor LLC | 569,041 | $10,874,000 | 3.97% |
| Logos Global Management LP | 1,525,000 | $29,143,000 | 3.58% |
| 1492 Capital Management LLC | 178,320 | $3,408,000 | 2.45% |
| Cormorant Asset Management, LP | 1,000,000 | $19,110,000 | 1.34% |
| MPM BioImpact LLC | 257,185 | $4,915,000 | 1.16% |
| Orbimed Advisors | 2,800,000 | $53,508,000 | 0.99% |
| SECTORAL ASSET MANAGEMENT INC | 220,985 | $4,223,000 | 0.83% |
| Rubric Capital Management LP | 472,047 | $9,021,000 | 0.45% |